#3536
Comparison of drug sensitivity profiles of various NEN spheroids
Introduction:
Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Small bowel and pancreatic NETs (SBNET & PNETs) are generally slow-growing but commonly metastasize to the liver and become aggressive cancers. Little is known about the drug sensitivity profile of these 3 NENs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NEN cells from patient tumors as patient-derived spheroids (PDS) and showed expression of NEN markers. The rarity and slow growing features of these spheroids have been hindering drug screens with many compounds.
Conference:
Presenting Author:
Ear P
Authors:
Tran C,
Luis B,
Sherman S,
Mudd J,
Abusada E,
Keywords:
NET,
NEC,
spheroid,
drug screening,
PDX model,
#3326
Drug sensitivity profiles of PNET, SBNET and NEC spheroids
Introduction:
Neuroendocrine neoplasms (NENs) are rare cancers that arise from neuroendocrine cells. NENs are classified as well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs). Few mutations have been identified for NETs from the small bowel (SBNETs) and pancreas (PNETs). SBNETs and PNETs are generally slow growing but they commonly metastasize to the liver and can become aggressive cancers. NECs often harbour mutations in key cell cycle genes (TP53 and RB) and are highly proliferative. Little is known about the drug sensitivity profile of SBNET, PNET and NECs due to the lack of cellular and animal models of these malignancies. Recently, we have developed a protocol to culture NET and NEC cells from patient tumors as patient-derived spheroids and showed that they express NEN markers.
Conference:
18th Annual ENETS Concerence (2021)
Presenting Author:
Ear P
Authors:
Ear P,
Tran C,
Li G,
Abusada E,
Mudd J,
Keywords:
PNET,
SBNET,
NEC,
drug testing,
spheroids,
#2898
Novel Preclinical Models of Small Bowel Neuroendocrine Tumors for Drug Screening
Introduction:
The incidence of neuroendocrine tumors (NETs) from the small bowel (SBNETs) has increased markedly over the past several decades. Many patients with these tumors present with metastatic disease, and research into new treatment options for these tumors have been hindered by the limited number of patient-derived SBNET cell lines and in vivo models available for drug testing.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Ear P
Authors:
Ear P,
Tran C,
Li G,
Kaemmer C,
Ellen A,
Keywords:
SBNET,
drug screening,
spheroids,
PDX models,
precision medicine,
